UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act 1934
Date
of
Report (date of earliest event reported): August
19, 2008
GENESIS
PHARMACEUTICALS ENTERPRISES, INC.
(Exact
name of registrant as specified in charter)
Florida
(State
or
other jurisdiction of incorporation)
333-86347
|
|
65-1130026
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
Middle
Section, Longmao Street, Area A, Laiyang Waixiangxing Industrial
Park
Laiyang
City, Yantai, Shandong Province, People’s Republic of China
265200
(Address
of principal executive offices and zip code)
(0086)535-7282997
(Registrant's
telephone number including area code)
(Registrant's
former name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to
Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
o Pre-commencement
communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On
August
19, 2008, the Company received confirmation from the Department of State of
Florida that the certificate of amendment to its articles of incorporation
to
increase the number of authorized shares of common stock from 600,000,000 to
900,000,000 was duly filed on July 29, 2008. A copy of the amendment is filed
as
an exhibit hereto.
Item
9.01 Financial
Statements and Exhibits.
Exhibit
No.
|
|
Description
|
3.1
|
|
Articles
of Amendment to the Registrant’s Articles of
Incorporation
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
GENESIS
PHARMACEUTICALS ENTERPRISES, INC.
|
|
|
/s/
Wubo Cao
|
|
Title:
Chief Executive Officer
|
Dated:
August 21, 2008